Deep dive into neuropathology

Imeka lets you see white matter like you've never seen it before.



We illuminate your data—from pipeline to product

Enhance your CNS drug development process with our revolutionary white matter imaging platform.

While diffusion MRI can pick up a signal from the white matter, standard data analysis procedures (DTI) cannot identify areas of interest or differentiate pathology from *complexity*.

Imeka can.

By combining diffusion MRI with artificial intelligence, Imeka can analyze white matter MRI signals in greater detail than anyone else. We can track crossing fibers, identify inflammation, and distinguish demyelination from axonal loss.

With our diffusion MRI analytic process you can learn if, how, and where in the brain your drugs are working. We call this *Imeka validation*, and it can change your whole pipeline development process for the better.

Enhance your CNS pipeline with our translational biomarkers

Our biomarkers are generated by our evolved and proprietary MI-Brain platform.

Composed of automatically extracted regions of interest and crucial microstructure elements, our biomarkers include:



Alzheimer's disease



Multiple Sclerosis

Fiber bundles: Medial temporal bundles; corpus callosum; posterier cingulum

Metrics:

Neuroinflammation Axonal loss Myelin index Fiber bundles: Lesion load dependent; normal-appearing white matter

Metrics: Myelin index Neuroinflammation Axonal loss



Parkinson's disease

Fiber bundles: Brain stem; thalamus; substantia nigra; motor cortex

Metrics:

Neuroinflammation Axonal loss Myelin index



Fiber bundles: 50 different fiber bundles

<u>Metrics:</u> Neuroinflammation Axonal loss Myelin index

We track and quantify measures that matter

WHAT WE MEASURE



Neuroinflammation,

EC: extracellular

by analyzing signals of free-water or extracellular space. Increased EC space




Myelin integrity, by analyzing free-water-corrected radial diffusivity.



Axonal integrity and white matter health, as indicated by apparent fiber density.

Our white matter imaging extracts extraordinarily detailed information from readily available MRI data.

HOW IT WORKS



You tell us the mechanism of action, and we tell you how that translates into imaging.

We coordinate image acquisition based on what you want to know.

We give you actionable answers based on artificial intelligence analysis of the data and our knowledge and expertise.

WHAT IT MEANS TO YOU

You get valuable information to help optimize your pipeline.

Optimize MRI time and streamline your pipeline

Imeka validation will help you move a molecule from candidate to product more efficiently.

IMEKA VALIDATION OPPORTUNITIES

PRECLINICAL


Refine the pipeline:

Remove ineffective/ inappropriate candidates before over-investing.

PHAŚE 1 [×] PHASE 2/2B

Accelerate the proof-of-concept

stages: Get early information from small sample trials on specific markers of neuroinflammation, axonal integrity, and/ or myelin content, including the type and magnitude of change.



PHASE 3

Streamline study recruitment: Select the right patients for your trials, based on validated markers of white matter microstructure along specific pathways.

Track and quantify

efficacy: Follow disease progression and drug efficacy longitudinally throughout your late-stage clinical trials.

RÈGISTRATION

Expedite the approval process:

Provide nuanced data to regulatory bodies to prove the therapeutic value of your product.



What is *your* area of focus?

Let's talk about what we can accomplish together.

Jean-René Bélanger | CEO

🔀 jr.belanger@imeka.ca

Gordon Starck | Sales Account Manager

🔀 jgordon.starck@imeka.ca

A little about Imeka

Imeka is currently the only company to combine diffusion imaging and AI to map white matter integrity and get insights on neuroinflammation, demyelination, and axonal loss. Our main goal is to play an influential role—and minimize risk—in the search for and development of cures for brain disease.

Imeka's imaging abilities are powerful, unique, and non-invasive. We truly believe any research and procedure involving the brain will benefit from our capabilities and our biomarker-generating platform for white matter imaging.

(in) linkedin.com/company/imeka/



© 2021 Imeka

